# Bio-Rad Laboratories Inc. (BIO-B) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare. Price $365.08, market value $9.8 billion.

## Valuation
- **P/E (trailing): 44.5×** (5-yr avg 8.1×, 3-yr avg 11.2×). Bio-Rad Laboratories Inc. trades at 44.5× trailing earnings, well above its own five-year average of 8.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 3.8×**. Each dollar of revenue is priced at 3.8×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 3.6%** (5-yr avg 2.6%). Free cash flow equals 3.6% of the market value, above its five-year average of 2.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.2%**. The inverse of the P/E: 2.2% of the price is earned each year.

## Profitability
- **Gross margin: 51.9%**. Bio-Rad Laboratories Inc. keeps 51.9% of revenue after the direct cost of what it sells.
- **Operating margin: 2.1%**. 2.1% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 29.4%**. 29.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.2%**. 10.2% on shareholders' equity is solid.
- **Return on invested capital: 0.4%**. Return on all capital, debt included, is 0.4%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 2.1%**. Each dollar of assets produces 2.1% of profit.

## Growth
- **Revenue growth (1 yr): 0.7%** (3-yr -2.7%/yr, 5-yr 0.3%/yr). Revenue grew 0.7% over the last year, against 0.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 142.6%** (5-yr -26.1%/yr). Earnings per share rose 142.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 66.2%/yr**. Free cash flow has compounded at 66.2% a year over three years.

## Financial health
- **Debt to equity: 0.16**. Debt is 0.16 times equity: a conservative balance sheet.
- **Interest coverage: 1.1×**. Operating profit covers interest only 1.1×: fragile.
- **Current ratio: 5.62** (quick 5.62). Current assets cover the next year's liabilities 5.62 times.
- **Altman Z-score: 3.39**. A Z-score of 3.39 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Bio-Rad Laboratories Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 47.8%** (YTD 17.5%, 3-mo 20.0%). The shares are up 47.8% over twelve months including dividends.
- **From 52-week high: 0.0%** (49.3% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 97**. An RSI of 97 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.14** (volatility 37%). Beta of 0.14 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BIO-B · Page: https://foliofundamentals.com/stocks/bio-b

Not investment advice.